Pharmacoeconomic analysis of naft idrofuryl in patients with chronic obliterating diseases of lower limb arteries
| Autor: | A. E. Cheberda, D. Yu. Belousov, M. R. Kuznetsov |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2018 |
| Předmět: | |
| Zdroj: | Качественная клиническая практика, Vol 0, Iss 4, Pp 15-32 (2018) |
| Druh dokumentu: | article |
| ISSN: | 2588-0519 2618-8473 |
| Popis: | Chronic obliterating diseases of lower limb arteries is a large group of socially significant diseases, characterized by persistent chronic progress, high probability of disabling complications as well as the emergence needs for expensive surgical treatment. This disease characterized by the association with other diseases of the cardiovascular system, making the conservative therapy especially relevant. Aim. To perform the pharmacoeconomic analysis (PHe) of the naft idrofuryl in the Russian Federation (RF) in patients aged 66 years and older with peripheral vascular disease, including atherosclerosis of the lower limbs arteries and the clinical picture, corresponding to Stage II of Fontaine. Methodology. Th is PHe is conducted perspective of public health organizations of the RF and considers only direct medical costs. Horizon of PHe adopted for 240 weeks (4.6 years). The source of data on the clinical eff ectiveness was taken from randomized controlled trials and meta-analyzes, which examined the efficacy, safety and tolerability comparable drugs. For criteria of clinical efficacy has been chosen the mean log expression of the maximum distance walk. As a criterion of utility were calculated the quality adjusted life years (QALY). In developed Markov model, the time horizon was broken down into a cycle of length for 1 week. On the basis of existing government standard of care was the assessment of costs in health care system for diagnosis and treatment in simulated groups, taking into consideration the cost of angioplasty. It was conducted cost-eff ectiveness (CEA), cost-utility (CUA), budget impact (BIA) and sensitivity analysis (SA), calculated cost-eff ectiveness threshold. Result. CER per patient at naft idrofuryl was 2,061 rubl., at pentoxifylline — 4,764 rubl. Since naft idrofuryl is not only superior to pentoxifylline in clinical effectiveness, but also was associated with a lower cost, the calculation of the ICER not needed. PHe show that CER per patient did not exceed the «willingness-to-pay ratio» none of the drugs, thus both of the drugs is relevant to reimbursement system. CUA demonstrated superiority naft idrofuryl both in terms of the net impact on the QALY, and in terms of utility costs (CUR), CUR of naft idrofuryl per patient totaled 144,992 rubl., pentoxifylline — 213,854 rubl. SA confi rmed the stability of these results. Analysis of BIA shows that the fi scal burden associated with naft idrofuryl, is lower by 183,9 million rubl. per year for every 3,000 treated patients on pentoxifylline, which can allow one to treat 1,321 patients more via a naft idrofuryl based therapeutic strategy. Conclusion. Excellence naft idrofuryl over pentoxifylline confi rmed in this pharmacoeconomic study. Naft idrofuryl dominates in terms of CER, CUR and reduce budget impact. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|